EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework

Luca Roeh, Nigel Schaeper iD, Sebastian Schröder, Jan Friedrich Scheitz, Dorothea Cornelia Voigt, Simon Schallenberg iD, Martin Janz, Philipp le Coutre, Sebastian Stintzing iD, Daniel Noerenberg

Current Oncology · 10.10.2026 · 33 (10) · 611

DOI: 10.3390/curroncol33100611 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 10.10.2026. Verfasst von Luca Roeh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Tumor Immunology, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universi…. Hauptthemen laut MEDLINE: Tretinoin, Leukemia, Promyelocytic, Acute, Arsenic Trioxide, Intracranial Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) is the standard of care for acute promyelocytic leukemia (APL), including high-risk disease. Secondary intracranial hypertension (SIH), historically termed pseudotumor cerebri (PTC), is a recognized but uncommon and potentially therapy-limiting complication of retinoid exposure, reported predominantly in pediatric and young-adult patients and most frequently during induction. We report a 31-year-old man with high-risk microgranular APL in whom SIH was diagnosed during the first ATRA/ATO consolidation cycle. The clinical course included progressive headache, ocular pain, pulsatile tinnitus, focusing difficulties, visual deterioration, and diplopia. Ophthalmological assessment demonstrated bilateral papilledema with marked peripapillary retinal nerve fiber layer thickening despite preserved central visual acuity. Magnetic resonance imaging showed bilateral optic nerve sheath distension, prominent optic nerve heads, mild pituitary flattening, and bilateral transverse sinus stenosis. Lumbar puncture demonstrated an opening pressure of 32 cm H2O with otherwise unremarkable cerebrospinal fluid; removal of approximately 30 mL resulted in immediate symptomatic improvement. Management consisted of temporary ATRA interruption, therapeutic lumbar punctures, acetazolamide, and individualized ATRA rechallenge and dose titration. Repeated attempts at dose escalation reproduced symptoms, and ATRA was ultimately maintained at a maximally tolerated dose of 30 mg/m2/day while full-dose ATO was continued. Molecular remission was achieved after the first consolidation cycle and remains sustained at 18-month follow-up. This case highlights the importance of recognizing ATRA-associated SIH throughout the treatment course and illustrates a pragmatic strategy for preserving ATRA exposure when standard-dose treatment is limited by neurological toxicity. However, the oncological equivalence of reduced-dose ATRA cannot be inferred from a single case.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TretinoinLeukemia, Promyelocytic, AcuteArsenic TrioxideIntracranial HypertensionAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAdult

Stichwörter der Autor:innen

acetazolamideacute promyelocytic leukemiaall-trans retinoic acidarsenic trioxideconsolidation therapypapilledemapseudotumor cerebrisecondary intracranial hypertension

Substanzen

TretinoinArsenic Trioxide

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Tumor Immunology, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Department of Internal Medicine, Bundeswehr Hospital Berlin, 10115 Berlin, Germany.
  • Department of Neurology with Experimental Neurology and Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berli…
  • Institute of Neuroradiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, German…

ORCID-Profile: Nigel Schaeper, Simon Schallenberg, Sebastian Stintzing

Zitieren

APA

Roeh, L., Schaeper, N., Schröder, S., Scheitz, J. F., Voigt, D. C., Schallenberg, S., Janz, M., le Coutre, P., Stintzing, S., & Noerenberg, D. (2026). Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework. Current Oncology, 33(10), 611. https://doi.org/10.3390/curroncol33100611

Vancouver

Roeh L, Schaeper N, Schröder S, Scheitz JF, Voigt DC, Schallenberg S, et al. Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework. Current Oncology. 2026;33(10):611. doi:10.3390/curroncol33100611

BibTeX
@article{Roeh2026,
  author = {Roeh, Luca and Schaeper, Nigel and Schröder, Sebastian and Scheitz, Jan Friedrich and Voigt, Dorothea Cornelia and Schallenberg, Simon and Janz, Martin and le Coutre, Philipp and Stintzing, Sebastian and Noerenberg, Daniel},
  title = {Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {10},
  pages = {611},
  doi = {10.3390/curroncol33100611}
}
Kostenlos starten →